Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
(2006) provide evidence in a recent issue of Molecular Cell to support the notion that elevated Nrf2 activity may also play a role in the evolution of cancer.
|
16543142 |
2006 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer Cells Upregulate NRF2 Signaling to Adapt to Autophagy Inhibition.
|
31378590 |
2019 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer cell survival depends on the balance between reactive oxygen species production and scavenging, which is mainly regulated by NRF2 during tumorigenesis.
|
31541481 |
2019 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Nrf2 knockout mice are greatly predisposed to chemical-induced DNA damage and exhibit higher susceptibility towards cancer development in several models of chemical carcinogenesis.
|
16054659 |
2005 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.
|
19321346 |
2009 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Nrf2 and its regulated genes and proteins are the targets of a major strategy in cancer prevention.
|
19940992 |
2010 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nrf2 is constitutively upregulated in several types of human cancer tissues and cancer cell lines.
|
20530669 |
2010 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
NF-E2-related factor 2 (Nrf2) is a major cytoprotective gene and is a key chemopreventive target against cancer and other diseases.
|
21487034 |
2011 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nuclear factor erythroid 2-related factor 2 (NRF2) activates expression of cytoprotective proteins such as GCLC and enhances cancer cell survival, whereas KEAP1 inhibits NRF2 by mediating NRF2 degradation.
|
23052169 |
2012 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Nuclear factor erythroid-derived 2-like 2 (Nrf2) is a critical regulator of key aspects of the antioxidant defense pathway and has long been a subject of interest regarding conditions of chronic stress such as inflammation and cancer.
|
23319124 |
2013 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
NF-E2-related factor 2 (Nrf2) is a pivotal transcription factor of cellular responses to oxidative stress and recent evidence suggests that Nrf2 plays an important role in cancer pathobiology.
|
23673813 |
2013 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
NRF2 also gives drug resistance of cancer cells through induction of detoxification and/or drug efflux proteins.
|
25467193 |
2014 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcription factor plays a dual role in cancer.
|
25918581 |
2015 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nrf2-overexpression in cancer cells results in chemo- and/or radioresistance.
|
26536456 |
2015 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Nrf2-ARE signaling has become an attractive target for cancer chemoprevention.
|
28267640 |
2017 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nrf2 is also activated in various cancer types due to genetic and epigenetic alterations, and is associated with poor survival and resistance to therapy.
|
28383481 |
2017 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Nuclear factor erythroid 2-related factor 2 (Nrf2; NFE2L2) is a master transcription regulator of stress responses and promotes metabolic reprogramming to support cell proliferation in various types of cancer.
|
29243822 |
2018 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nrf2 has demonstrated anti-inflammatory activity and can support cancer cell malignancy.
|
29603290 |
2018 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Nrf2 is a key regulator of the antioxidant defense system, and pharmacological Nrf2 activation is a promising strategy for cancer prevention and promotion of tissue repair.
|
30016619 |
2018 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Nrf2 has also been linked with increased risk of cancers, and cancer incidence certainly increases with age.
|
30695691 |
2019 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Nuclear factor, erythroid 2-like 2 (Nrf2) is a transcription factor that has been gaining attention in the field of pharmacology and especially in the chemoprevention of diseases such as cancer, metabolic and neurodegenerative diseases, etc.
|
31421134 |
2020 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nuclear factor (erythroid-derived 2)-like-2 factor (NRF-2) is a transcription factor well known to provide an advantage for cancer growth and survival regulating the cellular redox pathway.
|
31686530 |
2020 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Nrf2's role in cancer prevention, diagnosis, prognosis, and therapy is still in its infancy, and the future strategic planning of Nrf2-based oncological approaches should also consider the complex interaction between Nrf2 and its various activators and inhibitors.
|
31717324 |
2019 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
A big number of Nrf2-antioxidant response element activators have been screened for use as chemo-preventive drugs in OS associated diseases like cancer even though activation of Nrf2 happens in a variety of cancers.
|
31022969 |
2019 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A Complementary Chemical and Genomic Screening Approach for Druggable Targets in the Nrf2 Pathway and Small Molecule Inhibitors to Overcome Cancer Cell Drug Resistance.
|
29565554 |
2018 |